Greenwich, CT-based middle-market private equity investment firm focused on healthcare Amulet Capital Partners acquired SynteractHCR Holdings Corporation, a contract research organization (CRO) focused on Phase I‐IV clinical trials for emerging to mid-sized biopharma clients in the U.S., Europe and Asia.
Capital One and certain private debt funds managed by THL Credit Advisors provided debt financing for the transaction. SynteractHCR’s prior owner, Gryphon Investors, a middle-market private equity firm based in San Francisco, CA, acquired a majority interest in SynteractHCR in 2008 and supported the company’s growth into a global business.
The terms of the deals were not disclosed.
The company will use the proceeds to enhance its capabilities and hire more international clinical development experts to support global trials.
Founded in 1995 and headquartered outside San Diego, California, SynteractHCR is a full-service international contract research organization (CRO) supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development.
The company has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas including in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications.
With over 800 staff members across 21 countries led by CEO Wendel Barr, SynteractHCR has run over 3,500 projects including more than 700,000 patients in 60+ countries.